🧠✨Excited to announce that NanoNewron has secured a $2.5 million NIH STTR Phase 2 grant to advance our Alzheimer’s disease program!

IND submission expected next year.

More info: www.globenewswire.com/news-release...

#Alzheimers #NIH #Biotech #NanoNewron #NIHGrant

From insightful meetings to spontaneous hallway conversations — BIO2025 is full of energy and ideas.
Here’s our CEO, Dr. Marco Taglietti capturing the spirit of collaboration.

#BIO2025 #LeadershipInBiotech #NanoNewron

Rethinking Alzheimer’s Risk Factors. If inflammation drives neurodegeneration, could TNFα inhibitors slow or prevent Alzheimer’s? The evidence is growing, and the implications are huge. 🚀
#NanoNewron #AlzheimersResearch #Neurodegeneration #BrainHealth
#Neuroscience #Inflammation

The Future of Brain Medicine is Here 🚀🧬
What if biologics could reach the exact brain regions they’re needed in? Our highly specific, BBB-permeable platform makes targeted treatment a reality. #NanoNewron #BrainHealth #NeuroScience #Biotech
#MedicalInnovation #FutureOfMedicine

Double helix, big impact.🧬

Happy National DNA Day to the molecule that started it all.

#NationalDNADay #DNA #Genetics #Biotech #neuroscience #NanoNewron

We’re excited to share that our CEO will be taking the stage at the HELIX DISCOVERY SHOWCASE on April 29, 2025 to present NanoNewron — our bold step forward in biotech innovation.
Come see what the future looks like.
#HELIX2025 #nanonewron

Hope on the Horizon for Alzheimer’s Patients 💙
Imagine a future where effective treatments for neurodegeneration are no longer hindered by the Blood-Brain Barrier. With our TfR1-based biologic delivery platform, NewroBus™, that future is closer than ever. #AlzheimersResearch #NanoNewron

TNFα: Friend or Foe? While TNFα plays a key role in immune defense, chronic inflammation is linked to neurodegeneration. New studies suggest blocking TNFα could help reduce Alzheimer’s risk. Could this be a breakthrough in prevention? 🔬🧪
#NanoNewron #Neuroscience #AlzheimersResearch #TNFalpha

Brain Inflammation and Memory Loss-What’s the Link? Chronic inflammation has long been suspected in Alzheimer’s disease. Now, TNFα inhibitors show promise in reducing this risk. Are we on the verge of a game-changing discovery? 🚀
#NanoNewron #Neuroscience
#AlzheimersResearch #BrainHealth

Rutgers Startup Hopes Its Potentially Breakthrough Technology Will Improve Alzheimer’s Treatment NanoNewron, Inc., a startup founded based on technology developed at Rutgers, The State University of New Jersey, looks to advance its potentially game changing approach towards treating Alzheimer’s D...

research.rutgers.edu/news/rutgers...
#nanonewron #newrobus #alzheimers #research #biologics #biotech #brainhealth

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier...

www.globenewswire.com/news-release...

#nanonewron #newrobus #alzheimer’s #biotech #research #biologics #bloodbrainbarrier #brainhealth

At NanoNewron, we develop biologics that cross the blood-brain barrier to neutralize TNF-α, a key driver of neuroinflammation in Alzheimer’s & neurodegeneration. Our TfR1-mediated transcytosis platform enables targeted TNF-α inhibition to restore brain health.
#NanoNewron #newrobus #biotech